Zotarolimus

Zotarolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by preparation of the 42-triflate ester, followed by displacement with tetrazole and purification of the two isomeric products. This structural change affords a less bioavailable product, a preferred profile for some applications. Zotarolimus is extensively cited in the literature with over 200 citations.

Mechanism of Action	Zotarolimus binds to a receptor protein (FKBP12). The complex then binds to mTOR preventing it from interacting with target proteins.
Molecular Formula	C52H79N5O12
References	Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens. Burke S.E. et al. US Patent 7,357,942, 2008. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression Chen Y.W. et al. J. Cardiovasc. Pharmacol. 2007, 49, 228.